Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.

We characterized the HLA class I alterations in five metastases obtained from two patients with melanoma immunized with Melan A/MART-1, tyrosinase and gp100 tumor peptides. All three metastases analyzed in the first patient (NW145) showed a similar HLA class I alteration with a dual population of melanoma cells. One population was HLA class I antigen positive and the other had loss of heterozygosity (LOH) in the short arm of chromosome 6 leading to an HLA haplotype loss (A02011, B4007, Cw1). The absence of HLA-A2 antigen may explain why this patient did not develop HLA-A2 restricted, Melan A/MART-1 specificity immunization, since this HLA molecule is the restriction element for the tumor peptides used. However, this HLA-deficient population was not selected after peptide immunotherapy. The primary tumor in this patient presented LOH in region 6q, but only in the vertical growth phase of the lesion, whereas LOH at 6p was observed only in DNA from metastatic material. The second patient (NW16) also presented two metastatic lesions with an identical HLA molecular defect, i.e. HLA B locus downregulation (HLA B51011: serological B51; B1503: serological B70). One lesion expressed the tumor antigen (Melan A/ MART-1), but the other did not. Interestingly, the antigen-positive metastasis regressed after peptide immunotherapy, whereas the other progressed rapidly. These findings provide the first indication that multiple metastases generated in the same host can have identically altered HLA class I phenotypes.

[1]  F. Garrido,et al.  Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.

[2]  F. Garrido,et al.  Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.

[3]  N. Mehra,et al.  HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. , 2000, Human immunology.

[4]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[5]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[6]  P. Hersey,et al.  Impediments to successful immunotherapy. , 1999, Pharmacology & therapeutics.

[7]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[8]  F. Brasseur,et al.  Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.

[9]  D. Hicklin,et al.  beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. , 1998, The Journal of clinical investigation.

[10]  J. Zeuthen,et al.  In vivo and in vitro generation of a new altered HLA phenotype in melanoma‐tumour‐cell variants expressing a single HLA‐class‐I allele , 1998, International journal of cancer.

[11]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[12]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[13]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[14]  I. Macdonald,et al.  Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. , 1997, Invasion & metastasis.

[15]  K. Pantel,et al.  Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische Strategien , 1997, Der Chirurg.

[16]  Yao-Tseng Chen,et al.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[18]  F. Garrido,et al.  Characterization of a gastric tumor cell line defective in MHC class I inducibility by both α- and γ-interferon , 1996 .

[19]  F. Real,et al.  Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. , 1996, Tissue antigens.

[20]  F. Jotereau,et al.  Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.

[21]  J. Karbach,et al.  Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.

[22]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[23]  Yao-Tseng Chen,et al.  Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  X. Sastre,et al.  Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.

[25]  F. Garrido,et al.  HLA class I antigens in human tumors. , 1995, Advances in cancer research.

[26]  Cécile Fizames,et al.  The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.

[27]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[28]  Anne E. Kwitek,et al.  Dinucleotide repeat polymorphisms at the D11S419 and CD3D loci , 1990, Nucleic Acids Res..

[29]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[30]  J. Strominger,et al.  Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131 , 1985, The Journal of experimental medicine.

[31]  C. Milstein,et al.  Stimulation of HLA‐A,B,C by IFN‐alpha. The derivation of Molt 4 variants and the differential expression of HLA‐A,B,C subsets. , 1985, The EMBO journal.

[32]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.